10x Genomics Balance Sheet Health
Financial Health criteria checks 5/6
10x Genomics has a total shareholder equity of $741.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $965.1M and $224.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$388.70m |
| Equity | US$741.04m |
| Total liabilities | US$224.10m |
| Total assets | US$965.14m |
Recent financial health updates
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Feb 05
We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely
Nov 03Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Aug 04We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow
Feb 02Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Oct 05Recent updates
Why We're Not Concerned About 10x Genomics, Inc.'s (NASDAQ:TXG) Share Price
Apr 15Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Feb 0510x Genomics: Sales Are Growing At A Rapid Rate, But So Are Expenses
Jan 20Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%
Dec 22We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely
Nov 03Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Aug 04Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S
Jun 04At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?
Apr 2910x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate
Mar 24We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow
Feb 02Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?
Jan 12An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued
Dec 2210x Genomics: No Signs Of A Growth Turnaround, Heavy Bearish Momentum
Oct 12Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Oct 0510x Genomics cut to Sell at Goldman Sachs on slower sales ramp
Aug 1810x Genomics: Still Expensive, No Profitability In Sight, And Insiders Are Still Selling
Jul 3010x Genomics guides to Q2 revenues below consensus; shares down 13% after hours
Jul 14Financial Position Analysis
Short Term Liabilities: TXG's short term assets ($596.0M) exceed its short term liabilities ($127.2M).
Long Term Liabilities: TXG's short term assets ($596.0M) exceed its long term liabilities ($96.9M).
Debt to Equity History and Analysis
Debt Level: TXG is debt free.
Reducing Debt: TXG has no debt compared to 5 years ago when its debt to equity ratio was 127.6%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TXG has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if TXG has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.